LivaNova PLC (NASDAQ:LIVN) Given Average Rating of “Moderate Buy” by Analysts

LivaNova PLC (NASDAQ:LIVN) has been assigned an average rating of “Moderate Buy” from the nine research firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $65.6250.

Several equities analysts have recently issued reports on LIVN shares. KeyCorp initiated coverage on shares of LivaNova in a research note on Friday, December 19th. They issued an “overweight” rating and a $81.00 price objective on the stock. Wall Street Zen upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. Mizuho upped their price target on LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Robert W. Baird set a $75.00 price objective on LivaNova in a research note on Tuesday, December 16th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of LivaNova in a report on Monday, December 29th.

LivaNova Stock Up 1.4%

Shares of LIVN stock opened at $64.12 on Wednesday. LivaNova has a 1 year low of $32.48 and a 1 year high of $65.57. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.12 and a current ratio of 1.33. The business’s fifty day moving average is $59.40 and its 200-day moving average is $53.74. The stock has a market cap of $3.50 billion, a PE ratio of -16.03 and a beta of 0.97.

Institutional Trading of LivaNova

A number of hedge funds have recently bought and sold shares of LIVN. Primecap Management Co. CA increased its position in shares of LivaNova by 0.7% in the second quarter. Primecap Management Co. CA now owns 4,641,352 shares of the company’s stock worth $208,954,000 after acquiring an additional 32,942 shares in the last quarter. Millennium Management LLC boosted its stake in LivaNova by 22.4% in the 3rd quarter. Millennium Management LLC now owns 2,969,814 shares of the company’s stock worth $155,559,000 after purchasing an additional 544,033 shares during the period. Artisan Partners Limited Partnership grew its position in LivaNova by 94.5% during the 3rd quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock worth $127,129,000 after purchasing an additional 1,179,436 shares in the last quarter. Wellington Management Group LLP raised its stake in LivaNova by 83.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after purchasing an additional 1,067,349 shares during the period. Finally, AQR Capital Management LLC raised its stake in LivaNova by 30.5% during the 2nd quarter. AQR Capital Management LLC now owns 2,049,820 shares of the company’s stock valued at $92,201,000 after purchasing an additional 478,525 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.